Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

Romero, Alain J., Pogamp, Patrick Le, Nilsson, Lars‐Goran, Wood, Nolan·2002·Clinical Pharmacology & Therapeutics

Abstract

Objective: Voriconazole is a broad‐spectrum triazole antifungal agent under investigation for opportunistic infections that often target immunosuppressed patients. This study investigated the effect of voriconazole on the pharmacokinetics of cyclosporine (INN, ciclosporin). Methods: This was a randomized, double‐blind, placebo‐controlled, crossover study in kidney transplant recipients with stable renal function who were receiving cyclosporine (150‐375 mg/d). During the first study period (7.5 days), subjects in group A received concomitant voriconazole (200 mg every 12 hours); group B received a matched placebo. After a washout period (≥4 days), subjects were crossed over to the other treatment regimen. Results: In the 7 subjects who completed both regimens, concomitant administration with voriconazole resulted in a 1.7‐fold increase in mean cyclosporine area under the plasma concentration‐time curve within a dosage interval (AUC τ; 90% confidence interval, 1.47 to 1.96). Cyclosporine maximum observed plasma concentration (C max) and the time to the first occurrence of C max (t max) were not affected in a clinically significant manner, but plasma trough concentration (C min) was higher in the presence of voriconazole than with placebo. The mean increase in cyclosporine C min in subjects who ceased to participate in the study was 2.48‐fold (range, 1.88 to 3.03). There were 7 subjects who stopped participating in the study during voriconazole administration. Six of these subjects discontinued the study for reasons that were considered to be drug related, and the majority were attributable to increased cyclosporine levels. Although not serious, all causality‐related adverse events were more frequent during voriconazole administration than during placebo administration. Conclusions: Mean cyclosporine AUC τ increased 1.7‐fold in the presence of voriconazole. Therefore, when voriconazole is initiated in patients already receiving cyclosporine, it is recommended that the cyclosporine dose be halved and that blood cyclosporine concentrations be carefully monitored. When voriconazole is discontinued, blood cyclosporine concentrations should be monitored and the cyclosporine dose increased, if necessary. Clinical Pharmacology & Therapeutics (2002) 71, 226–234; doi: 10.1067/mcp.2002.121911

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1067/mcp.2002.121911

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Romero, A. J., Pogamp, P. L., Nilsson, L., & Wood, N.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-04
Volume
71
Issue
4
Pages
226-234
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2136517919
Cited by
169
References
0
FWCI
9.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. https://app.cochat.ai/papers/10.1067/mcp.2002.121911
The paper
Romero, A. J., Pogamp, P. L., Nilsson, L., & Wood, N. (2002). Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.121911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.